Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2011

Inhalt (36 Artikel)

Preclinical study

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status

Hyun Mi Kim, Choung-Soo Kim, Je-Hwan Lee, Se Jin Jang, Jung Jin Hwang, Seonggu Ro, Young-Lan Hyun, Jene Choi

Preclinical study

Significance of ER–Src axis in hormonal therapy resistance

Sreeram Vallabhaneni, Binoj C. Nair, Valerie Cortez, Rambabu Challa, Dimple Chakravarty, Rajeshwar Rao Tekmal, Ratna K. Vadlamudi

Preclinical Study

Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase

Puspa R. Pandey, Hiroshi Okuda, Misako Watabe, Sudha K. Pai, Wen Liu, Aya Kobayashi, Fei Xing, Koji Fukuda, Shigeru Hirota, Tamotsu Sugai, Go Wakabayashi, Keisuke Koeda, Masahiro Kashiwaba, Kazuyuki Suzuki, Toshimi Chiba, Masaki Endo, Tomoaki Fujioka, Susumu Tanji, Yin-Yuan Mo, Deliang Cao, Andrew C. Wilber, Kounosuke Watabe

Preclinical study

P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis

Robin Fuchs-Young, Stephanie H. Shirley, Isabel Lambertz, Jennifer K. L. Colby, Jie Tian, Dennis Johnston, Irma B. Gimenez-Conti, Lawrence A. Donehower, Claudio J. Conti, Stephen D. Hursting

Preclinical study

Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance

Thomas Karn, Eugen Ruckhäberle, Lars Hanker, Volkmar Müller, Marcus Schmidt, Christine Solbach, Regine Gätje, Mathias Gehrmann, Uwe Holtrich, Manfred Kaufmann, Achim Rody

Preclinical study

A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients

M. A. Didraga, E. H. van Beers, S. A. Joosse, K. I. M. Brandwijk, R. A. Oldenburg, L. F. A. Wessels, F. B. L. Hogervorst, M. J. Ligtenberg, N. Hoogerbrugge, S. Verhoef, P. Devilee, P. M. Nederlof

Preclinical study

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy

Scott Thomas, Kenneth T. Thurn, Elona Biçaku, Douglas C. Marchion, Pamela N. Münster

Preclinical study

Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

Cristina Raimondi, Angela Gradilone, Giuseppe Naso, Bruno Vincenzi, Arianna Petracca, Chiara Nicolazzo, Antonella Palazzo, Rosa Saltarelli, Franco Spremberg, Enrico Cortesi, Paola Gazzaniga

Preclinical study

Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study

D. G. Powe, M. J. Voss, H. O. Habashy, K. S. Zänker, A. R. Green, I. O. Ellis, F. Entschladen

Preclinical study

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

M. P. Roberti, M. M. Barrio, A. I. Bravo, Y. S. Rocca, J. M. Arriaga, M. Bianchini, J. Mordoh, E. M. Levy

Clinical trial

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

Sibylle Loibl, Berit Maria Müller, Gunter von Minckwitz, Michael Schwabe, Marc Roller, Silvia Darb-Esfahani, Beyhan Ataseven, Andreas du Bois, Annette Fissler-Eckhoff, Bernd Gerber, Uwe Kulmer, Jens-Uwe Alles, Keyur Mehta, Carsten Denkert

Clinical trial

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments

Yahong Wang, Quangui Yin, Qi Yu, Jing Zhang, Ziyu Liu, Shuling Wang, Shuhua Lv, Yun Niu

Clinical trial

Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype

Hee Jeong Kim, Wonshik Han, On Vox Yi, Hee Chul Shin, Soo-Kyung Ahn, Beom Seok Koh, Hyeong-Gon Moon, Jong Han You, Byung Ho Son, Sei Hyun Ahn, Dong-Young Noh

Clinical Trial

Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society

Sei Hyun Ahn, Hee Jeong Kim, Jong Won Lee, Gyung-Yub Gong, Dong-Yong Noh, Jung Hyun Yang, Sang Seol Jung, Ho Yong Park

Epidemiology

Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case–control study

Xiao-Feng He, Jiao Su, Ying Zhang, Xian Huang, Yi Liu, Da-Peng Ding, Wei Wang, K. Arparkorn

Epidemiology

Unmet supportive care needs: a cross-cultural comparison between Hong Kong Chinese and German Caucasian women with breast cancer

Wendy W. T. Lam, Angel H. Y. Au, Jennifer H. F. Wong, Claudia Lehmann, Uwe Koch, Richard Fielding, Anja Mehnert

Epidemiology

Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening

R. Román, M. Sala, M. De La Vega, C. Natal, J. Galceran, I. González-Román, A. Baroja, R. Zubizarreta, N. Ascunce, D. Salas, X. Castells

Epidemiology

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden

Theodoros Foukakis, Tommy Fornander, Tobias Lekberg, Henrik Hellborg, Jan Adolfsson, Jonas Bergh

Epidemiology

Association between polymorphisms of the renin–angiotensin system genes and breast cancer risk: a meta-analysis

Bo Xi, Tao Zeng, Liu Liu, Yajun Liang, Weina Liu, Yuehua Hu, Jun Li

Epidemiology

Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy

Lisa Gallicchio, Ryan MacDonald, Bethany Wood, Errol Rushovich, Kathy J. Helzlsouer

Epidemiology

Long-term course of pain in breast cancer survivors: a 4-year longitudinal study

Winfried Rief, Wayne A. Bardwell, Joel E. Dimsdale, Loki Natarajan, Shirley W. Flatt, John P. Pierce

Epidemiology

Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger

Mia M. Gaudet, Michael F. Press, Robert W. Haile, Charles F. Lynch, Sally L. Glaser, Joellen Schildkraut, Marilie D. Gammon, W. Douglas Thompson, Jonine L. Bernstein

Epidemiology

Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups

Alexandra J. van den Broek, Annegien Broeks, Hugo M. Horlings, Sander V. M. Canisius, Linde M. Braaf, Anita Langerød, Laura J. Van’t Veer, Marjanka K. Schmidt

Epidemiology

Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses

Voralak Vichapat, Hans Garmo, Lars Holmberg, Ian S. Fentiman, Andrew Tutt, Cheryl Gillett, Margreet Lüchtenborg

Epidemiology

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care

Jennifer S. Haas, Su-Ying Liang, Michael J. Hassett, Stephen Shiboski, Elena B. Elkin, Kathryn A. Phillips

Epidemiology

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey

K. Kawaguchi, H. Ishiguro, S. Morita, S. Nakamura, S. Ohno, N. Masuda, H. Iwata, K. Aogi, K. Kuroi, M. Toi

Epidemiology

Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity

Rita A. Mukhtar, Amy P. Moore, Onouwem Nseyo, Frederick L. Baehner, Alfred Au, Dan H. Moore, Patrick Twomey, Michael J. Campbell, Laura J. Esserman

Epidemiology

CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes

Fangfang Liu, Ronggang Lang, Jing Zhao, Xinmin Zhang, Gordon A. Pringle, Yu Fan, Dong Yin, Feng Gu, Zhi Yao, Li Fu

Epidemiology

COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin

Michelle D. Holmes, Wendy Y. Chen, Stuart J. Schnitt, Laura Collins, Graham A. Colditz, Susan E. Hankinson, Rulla M. Tamimi

Brief Report

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA

Mark Mackiewicz, Konrad Huppi, Jason J. Pitt, Tiffany H. Dorsey, Stefan Ambs, Natasha J. Caplen

Brief Report

What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

Dora Il’yasova, Sharareh Siamakpour-Reihani, Igor Akushevich, Lucy Akushevich, Neil Spector, Joellen Schildkraut

Brief Report

Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer

Evan I. Blumgart, Roger F. Uren, Poul M. F. Nielsen, Martyn P. Nash, Hayley M. Reynolds

Letter to the Editor

A Halsted mastectomy 21 years before Halsted

Gregory Tsoucalas, Antonis A. Kousoulis, Lazaros Vladimiros, George Androutsos

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.